[go: up one dir, main page]

DK0746613T3 - Rekombinante humaniserede antistoffer mod FB5 - Google Patents

Rekombinante humaniserede antistoffer mod FB5

Info

Publication number
DK0746613T3
DK0746613T3 DK95913660T DK95913660T DK0746613T3 DK 0746613 T3 DK0746613 T3 DK 0746613T3 DK 95913660 T DK95913660 T DK 95913660T DK 95913660 T DK95913660 T DK 95913660T DK 0746613 T3 DK0746613 T3 DK 0746613T3
Authority
DK
Denmark
Prior art keywords
humanized
antibodies
specific antibodies
provides
specific
Prior art date
Application number
DK95913660T
Other languages
English (en)
Inventor
Francis J Carr
Lloyd J Old
Thomas P Wallace
Wolfgang J Rettig
Pilar Garin-Chesa
William J Harris
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of DK0746613T3 publication Critical patent/DK0746613T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95913660T 1994-03-08 1995-03-08 Rekombinante humaniserede antistoffer mod FB5 DK0746613T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20777894A 1994-03-08 1994-03-08

Publications (1)

Publication Number Publication Date
DK0746613T3 true DK0746613T3 (da) 2006-09-25

Family

ID=22771976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95913660T DK0746613T3 (da) 1994-03-08 1995-03-08 Rekombinante humaniserede antistoffer mod FB5

Country Status (8)

Country Link
US (4) US5811522A (da)
EP (1) EP0746613B1 (da)
AT (1) ATE327330T1 (da)
AU (1) AU688880B2 (da)
CA (1) CA2185116A1 (da)
DE (1) DE69535002T2 (da)
DK (1) DK0746613T3 (da)
WO (1) WO1995024483A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE69535002T2 (de) * 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
JP4928259B2 (ja) * 2003-03-04 2012-05-09 キリンホールディングス株式会社 内皮細胞特異的抗体およびその使用
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
AU2005326758B2 (en) * 2004-06-23 2011-07-14 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
CA2590583A1 (en) * 2004-12-03 2006-06-08 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
CA2607455A1 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
WO2008124570A1 (en) 2007-04-05 2008-10-16 Morphotek, Inc. Methods for inhibiting the binding of endosialin to ligands
EA009327B1 (ru) * 2007-04-27 2007-12-28 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины на основе поверхностных антигенов эндотелиальных клеток
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US20120100111A1 (en) * 2009-03-06 2012-04-26 Universite Paris Descartes Method for treating cancer
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
MX2017003546A (es) 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
SG10202100268RA (en) 2016-08-13 2021-02-25 United Biopharma Inc Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5342757A (en) * 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE69535002T2 (de) * 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5

Also Published As

Publication number Publication date
AU688880B2 (en) 1998-03-19
US6391302B1 (en) 2002-05-21
WO1995024483A1 (en) 1995-09-14
DE69535002T2 (de) 2006-12-07
US6090930A (en) 2000-07-18
DE69535002D1 (de) 2006-06-29
CA2185116A1 (en) 1995-09-14
AU1996495A (en) 1995-09-25
US5811522A (en) 1998-09-22
EP0746613B1 (en) 2006-05-24
EP0746613A1 (en) 1996-12-11
ATE327330T1 (de) 2006-06-15
US6217868B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
DK0746613T3 (da) Rekombinante humaniserede antistoffer mod FB5
DK0749482T3 (da) Rekombinante humaniserede anti-Lewis Y antistoffer
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
HUT52153A (en) Process for producing chimeric antibody specific to human tumour antigene
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
ES8900247A1 (es) Un metodo de detecion y diagnostico de cancer empleando un nuevo antigeno asociado a un tumor.
ES8800603A1 (es) Un metodo para producir anticuerpos monoclonales
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
EP0242154A3 (en) A novel tumor-associated antigen
AU5790390A (en) A novel tumor associated antigen
SE8401946D0 (sv) Antibody to human prostate cancer
EP0185135A3 (en) Novel monoclonal antibody
JPS6444856A (en) Anti-cancer antigen anti-serum
FI961439L (fi) Menetelmä terapeuttisesti käyttökelpoisen vasta-aineen tai vasta-ainefragmentin valmistamiseksi